Haemonetics Stock Performance
| HAE Stock | USD 70.09 0.00 0.00% |
Haemonetics has a performance score of 5 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.92, which attests to possible diversification benefits within a given portfolio. Haemonetics returns are very sensitive to returns on the market. As the market goes up or down, Haemonetics is expected to follow. Haemonetics right now retains a risk of 2.13%. Please check out Haemonetics downside deviation, total risk alpha, value at risk, as well as the relationship between the information ratio and treynor ratio , to decide if Haemonetics will be following its current trending patterns.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Haemonetics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent basic indicators, Haemonetics may actually be approaching a critical reversion point that can send shares even higher in July 2025. ...more
Actual Historical Performance (%)
One Day Return (1.78) | Five Day Return (3.06) | Year To Date Return (10.60) | Ten Year Return 64.53 | All Time Return 1.1 K |
Last Split Factor 2:1 | Last Split Date 2012-12-03 |
1 | Q4 Earnings Highs And Lows Haemonetics Vs The Rest Of The Medical Devices Supplies - Specialty Stocks - Yahoo Finance | 04/04/2025 |
2 | Insider Trading | 04/07/2025 |
3 | Disposition of 337 shares by Anila Lingamneni of Haemonetics at 96.49 subject to Rule 16b-3 | 04/23/2025 |
4 | Haemonetics Co. Given Average Rating of Moderate Buy by Brokerages | 05/02/2025 |
5 | Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website | 05/08/2025 |
6 | HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up | 05/12/2025 |
7 | Disposition of 2391 shares by Simon, Christopher of Haemonetics at 69.38 subject to Rule 16b-3 | 05/15/2025 |
8 | Disposition of 622 shares by Michelle Basil of Haemonetics at 69.38 subject to Rule 16b-3 | 05/19/2025 |
9 | Citi shuffles MedTech stocks BDX downgraded, ITGR raised reiterates top pick | 05/22/2025 |
10 | Haemonetics Full Year 2025 Earnings EPS Beats Expectations | 05/23/2025 |
11 | Upcoming Management Conference Call for HAE Scheduled by JPMorgan HAE Stock News | 05/30/2025 |
12 | Disposition of 1246 shares by James Darecca of Haemonetics at 70.31 subject to Rule 16b-3 | 06/03/2025 |
13 | Acquisition by Farris Maunsell of 2662 shares of Haemonetics subject to Rule 16b-3 | 06/05/2025 |
14 | Market Participants Recognise Haemonetics Corporations Earnings | 06/10/2025 |
| Begin Period Cash Flow | 178.8 M |
Haemonetics | Build AI portfolio with Haemonetics Stock |
Haemonetics Relative Risk vs. Return Landscape
If you would invest 6,468 in Haemonetics on March 18, 2025 and sell it today you would earn a total of 541.00 from holding Haemonetics or generate 8.36% return on investment over 90 days. Haemonetics is generating 0.1476% of daily returns assuming volatility of 2.1326% on return distribution over 90 days investment horizon. In other words, 19% of stocks are less volatile than Haemonetics, and above 98% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Haemonetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Haemonetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Haemonetics, and traders can use it to determine the average amount a Haemonetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0692
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | HAE | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.13 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.15 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Haemonetics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Haemonetics by adding it to a well-diversified portfolio.
Haemonetics Fundamentals Growth
Haemonetics Stock prices reflect investors' perceptions of the future prospects and financial health of Haemonetics, and Haemonetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Haemonetics Stock performance.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0665 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 4.29 B | ||||
| Shares Outstanding | 48.04 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 4.10 X | ||||
| Price To Sales | 2.47 X | ||||
| Revenue | 1.36 B | ||||
| Gross Profit | 778.55 M | ||||
| EBITDA | 221.82 M | ||||
| Net Income | 167.68 M | ||||
| Cash And Equivalents | 284.47 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 303.56 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 17.02 X | ||||
| Cash Flow From Operations | 181.72 M | ||||
| Earnings Per Share | 3.31 X | ||||
| Market Capitalization | 3.37 B | ||||
| Total Asset | 2.45 B | ||||
| Retained Earnings | 352.17 M | ||||
| Working Capital | 356.86 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
About Haemonetics Performance
By analyzing Haemonetics' fundamental ratios, stakeholders can gain valuable insights into Haemonetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Haemonetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Haemonetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 217.82 | 119.29 | |
| Return On Tangible Assets | 0.12 | 0.05 | |
| Return On Capital Employed | 0.12 | 0.07 | |
| Return On Assets | 0.07 | 0.04 | |
| Return On Equity | 0.20 | 0.06 |
Things to note about Haemonetics performance evaluation
Checking the ongoing alerts about Haemonetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Haemonetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Market Participants Recognise Haemonetics Corporations Earnings |
- Analyzing Haemonetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Haemonetics' stock is overvalued or undervalued compared to its peers.
- Examining Haemonetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Haemonetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Haemonetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Haemonetics' stock. These opinions can provide insight into Haemonetics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stocks Directory Find actively traded stocks across global markets |